Everyone knows all that really matters is an MHRA approval. Most of the talk on that “other” board is just rehashing the same set of opinions, many of them disingenuous, but others are just restatements of prior positions with no new information behind them.
I know some things other people don’t know – like conversations I've had at medical conferences with some of the clinical trial investigators (and they strongly believe in the therapy), and several other topics – but none of it is conclusive and I don’t know if MHRA will grant approval. Approvals always carry risk. They’re mostly about the data and trial design but they’re also about unmet medical needs and incentives within agencies. The company has a shot and if the therapy is approved everything changes… credibility, financing options, combo-trials etc.
News 
Market Data 
Discover 
AI
